October 20, 2011 (Amsterdam, the Netherlands) — A new investigation finds that 6 years after diagnosis, brain volumes and, particularly, cognition were more severely affected in men with multiple ...

Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly ...

After menopause, women with multiple sclerosis experienced accelerated volume loss in global gray matter, the left hippocampus, and the left anterior cingulate, highlighting the menopausal transition ...

A cross-sectional, prospective study found that gray matter atrophy was more prevalent in patients with more severe progressive multiple sclerosis (MS) compared with those with less severe progressive ...

Brain lesions — areas of brain tissue that show damage from injury or disease — are the biomarker most widely used to determine multiple sclerosis disease progression. But an innovative new study led ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

"We plan to analyze these MRI structural measures longitudinally to determine if changes in brain volumes or lesion burden over time contribute to fatigue trajectories. More broadly, we might ...

Vascular comorbidities, including diabetes and hypertension, are linked to significantly lower measures of neurologic function in people with multiple sclerosis (MS) vs patients without these ...

As adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay diet went up, total grey matter decline and ...